✦ LIBER ✦

Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas

✍ Scribed by Victor A Levin; Sandra Ictech; Kenneth R Hess

Book ID: 115010991
Publisher: BioMed Central
Year: 2007
Tongue: English
Weight: 343 KB
Volume: 7
Category: Article
ISSN: 1471-2407
DOI: 10.1186/1471-2407-7-106

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

4010 POSTER Satraplatin increases progre

4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients

✍ C. Sternberg; O. Sartor; D. Petrylak; J.A. Witjes; I. Bodrogi; P. Harper; J.P. D 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Consolidation with alemtuzumab improves

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

✍ Carmen D. Schweighofer; Matthias Ritgen; Barbara F. Eichhorst; Raymonde Busch; W 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

Intermittent/alternated therapy with tam

Intermittent/alternated therapy with tamoxifen and medroxy-progesterone acetate prolongs time to resistance to tamoxifen without benefit for (progression free) survival in patients with advanced breast cancer. Results of an EORTC phase III study (trial 10863)

✍ L Beex; C Rose; H Mouridsen; J Jassem; M Nooy; J Estape; R Paridaens; M.J Piccar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 172 KB

4.13 Proposal of a New Prognostic Score

4.13 Proposal of a New Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on an Overall Survival Analysis of Three German CLL Study Group Phase III Trials

✍ Jasmin Bahlo; Natali Pflug; Thomas Elter; Kathrin Bauer; Barbara Eichhorst; Manu 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 130 KB

Effect of celecoxib on survival in patie

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

✍ Andrea Koch; Bengt Bergman; Erik Holmberg; Christer Sederholm; Lars Ek; Jaroslaw 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 504 KB

A VM 26-based regimen for patients with

A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma. Prolonged disease-free survival in patients younger than 60 years of age: A phase II trial of the eastern cooperative oncology group

✍ Leo I. Gordon; Janet Andersen; Stephanie Gregory; Joseph Mazza; Paul Chervenick; 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 545 KB

Background. The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase I1 trial of a novel chemotherapy regimen was conducted